New Alpha-Particle therapy targets Hard-to-Treat tumors

NCT ID NCT05636618

Recruiting now Disease control Sponsor: Perspective Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called [212Pb]VMT-α-NET, which delivers a powerful type of radiation (alpha particles) directly to tumor cells that have a specific marker (SSTR2). The trial includes 300 adults with advanced neuroendocrine tumors or meningioma that cannot be removed by surgery. The goal is to find the safest dose and see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [212Pb]VMT-α-NET (a radioactive drug that delivers alpha particles directly to tumor cells)
What this could lead to: If successful, this could provide a new treatment option for patients with advanced neuroendocrine tumors or meningioma that have not responded to other therapies.
What could go wrong: This is an early first-in-human trial, so safety and effectiveness are not yet known. The treatment involves radiation, which may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchial endocrine tumor digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2 meningioma neuroendocrine neoplasm paraganglioma pheochromocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHIAL NEUROENDOCRINE TUMOR GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR MENINGIOMA NEUROENDOCRINE TUMOR METASTATIC NEUROENDOCRINE TUMORS UNRESECTABLE PARAGANGLIOMA PHEOCHROMOCYTOMA

Contacts and locations

Show contact details

Locations

BAMF Health
RECRUITING

Grand Rapids, Michigan, 49503, United States
Barbara Ann Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Biogenix Molecular
RECRUITING

Miami, Florida, 33165, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States

Contact Email: •••••@•••••
Froedtert Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Johns Hopkins
RECRUITING

Baltimore, Maryland, 21287, United States
Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States

Contact Email: •••••@•••••
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Michigan Health Professionals
RECRUITING

Troy, Michigan, 48098, United States
Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68130, United States
Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
The University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States

Contact Email: •••••@•••••
UH Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States
University of Iowa
RECRUITING

Iowa City, Iowa, 52242, United States
University of Kentucky
RECRUITING

Lexington, Kentucky, 40536, United States
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27599, United States
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.